Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 314


Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.

Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S.

J Bone Oncol. 2017 Aug 31;8:18-22. doi: 10.1016/j.jbo.2017.08.004. eCollection 2017 Sep.


Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: Solving substrate interactions of CYP1A2 with non-PAH substrates on the template system.

Yamazoe Y, Yoshinari K.

Drug Metab Pharmacokinet. 2017 Oct;32(5):229-247. doi: 10.1016/j.dmpk.2017.05.004. Epub 2017 May 29.


Introduction of an N-Glycosylation Site into UDP-Glucuronosyltransferase 2B3 Alters Its Sensitivity to Cytochrome P450 3A1-Dependent Modulation.

Nakamura T, Yamaguchi N, Miyauchi Y, Takeda T, Yamazoe Y, Nagata K, Mackenzie PI, Yamada H, Ishii Y.

Front Pharmacol. 2016 Nov 14;7:427. eCollection 2016.


Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals.

Yamazoe Y, Ito K, Yamamura Y, Iwama R, Yoshinari K.

Drug Metab Pharmacokinet. 2016 Oct;31(5):363-384. doi: 10.1016/j.dmpk.2016.07.005. Epub 2016 Aug 10.


Activation of p38 Mitogen-Activated Protein Kinase by Clotrimazole Induces Multidrug Resistance-Associated Protein 3 Activation through a Novel Transcriptional Element.

Sasaki T, Inami K, Numata Y, Funakoshi K, Yoshida M, Kumagai T, Kanno S, Matsui S, Toriyabe T, Yamazoe Y, Yoshinari K, Nagata K.

J Pharmacol Exp Ther. 2016 Oct;359(1):102-9. doi: 10.1124/jpet.115.231589. Epub 2016 Aug 9.


Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Hasunuma T, Tohkin M, Kaniwa N, Jang IJ, Yimin C, Kaneko M, Saito Y, Takeuchi M, Watanabe H, Yamazoe Y, Uyama Y, Kawai S.

Br J Clin Pharmacol. 2016 Jun;81(6):1078-90. doi: 10.1111/bcp.12884. Epub 2016 Mar 14.


Performance of 11C-Pittsburgh Compound B PET Binding Potential Images in the Detection of Amyloid Deposits on Equivocal Static Images.

Hosokawa C, Ishii K, Kimura Y, Hyodo T, Hosono M, Sakaguchi K, Usami K, Shimamoto K, Yamazoe Y, Murakami T.

J Nucl Med. 2015 Dec;56(12):1910-5. doi: 10.2967/jnumed.115.156414. Epub 2015 Sep 10.


Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region.

Miyauchi Y, Nagata K, Yamazoe Y, Mackenzie PI, Yamada H, Ishii Y.

Mol Pharmacol. 2015 Oct;88(4):800-12. doi: 10.1124/mol.115.098582. Epub 2015 Aug 4.


Authors' response to Letter to the Editor by Jeff Kelsey et al. "Response to 'Development of a category approach to predict the testicular toxicity of chemical substances structurally related to ethylene glycol methyl ether.'" 2015.

Yamada T, Tanaka Y, Hasegawa R, Sakuratani Y, Yamazoe Y, Ono A, Hirose A, Hayashi M.

Regul Toxicol Pharmacol. 2015 Oct;73(1):209. doi: 10.1016/j.yrtph.2015.07.002. Epub 2015 Jul 9. No abstract available.


Antibacterial drug treatment increases intestinal bile acid absorption via elevated levels of ileal apical sodium-dependent bile acid transporter but not organic solute transporter α protein.

Miyata M, Hayashi K, Yamakawa H, Yamazoe Y, Yoshinari K.

Biol Pharm Bull. 2015;38(3):493-6. doi: 10.1248/bpb.b14-00640. Epub 2014 Dec 27.


Development of a category approach to predict the testicular toxicity of chemical substances structurally related to ethylene glycol methyl ether.

Yamada T, Tanaka Y, Hasegawa R, Sakuratani Y, Yamazoe Y, Ono A, Hirose A, Hayashi M.

Regul Toxicol Pharmacol. 2014 Dec;70(3):711-9. doi: 10.1016/j.yrtph.2014.10.011. Epub 2014 Oct 27.


Investigation of (11)C-PiB equivocal PET findings.

Hosokawa C, Ishii K, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, Yamazoe Y, Hosono M, Hanada K, Ueda M, Saigo K, Murakami T.

Ann Nucl Med. 2015 Feb;29(2):164-9. doi: 10.1007/s12149-014-0924-8. Epub 2014 Nov 6.


Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition.

Ishii K, Hosokawa C, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, Hosono M, Yamazoe Y, Murakami T.

Ann Nucl Med. 2015 Jan;29(1):78-83. doi: 10.1007/s12149-014-0911-0. Epub 2014 Oct 1.


Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.

Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K.

PLoS One. 2014 Jul 14;9(7):e101902. doi: 10.1371/journal.pone.0101902. eCollection 2014.


SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells.

Miyata M, Hata T, Yamazoe Y, Yoshinari K.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):477-82. doi: 10.1016/j.bbrc.2013.11.126. Epub 2013 Dec 7.


Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants.

Ishii Y, Koba H, Kinoshita K, Oizaki T, Iwamoto Y, Takeda S, Miyauchi Y, Nishimura Y, Egoshi N, Taura F, Morimoto S, Ikushiro S, Nagata K, Yamazoe Y, Mackenzie PI, Yamada H.

Drug Metab Dispos. 2014 Feb;42(2):229-38. doi: 10.1124/dmd.113.054833. Epub 2013 Nov 19.


[A search for the risk factors for hiccups and evaluation of antiemetic therapy in CDDP-based chemotherapy, using cluster analysis].

Asano H, Watanabe M, Kawaguchi A, Yanae M, Funakami Y, Wada T, Matzno S, Yamazoe Y, Nishida S, Ichida S.

Gan To Kagaku Ryoho. 2013 Aug;40(8):1031-6. Japanese.


Ileal apical sodium-dependent bile acid transporter protein levels are down-regulated through ubiquitin-dependent protein degradation induced by bile acids.

Miyata M, Yamakawa H, Hayashi K, Kuribayashi H, Yamazoe Y, Yoshinari K.

Eur J Pharmacol. 2013 Aug 15;714(1-3):507-14. doi: 10.1016/j.ejphar.2013.06.036. Epub 2013 Jul 18.


Dual roles of nuclear receptor liver X receptor α (LXRα) in the CYP3A4 expression in human hepatocytes as a positive and negative regulator.

Watanabe K, Sakurai K, Tsuchiya Y, Yamazoe Y, Yoshinari K.

Biochem Pharmacol. 2013 Aug 1;86(3):428-36. doi: 10.1016/j.bcp.2013.05.016. Epub 2013 May 31.


[TDM management system for contribution to proper use of anti-mRSA drugs--establishment of cooperation support system between pharmacy and clinical laboratory in hospital].

Yodoshi M, Iwasaki N, Satoh K, Nomura M, Morishima Y, Nakae K, Yamazoe Y.

Rinsho Byori. 2013 Feb;61(2):127-34. Japanese.


Xenobiotic-induced hepatocyte proliferation associated with constitutive active/androstane receptor (CAR) or peroxisome proliferator-activated receptor α (PPARα) is enhanced by pregnane X receptor (PXR) activation in mice.

Shizu R, Benoki S, Numakura Y, Kodama S, Miyata M, Yamazoe Y, Yoshinari K.

PLoS One. 2013 Apr 23;8(4):e61802. doi: 10.1371/journal.pone.0061802. Print 2013.


New parameter that supports speculation on the possible mechanism of hypothyroidism induced by chemical substances in repeated-dose toxicity studies.

Yamada T, Hasegawa R, Nishikawa S, Sakuratani Y, Yamada J, Yamashita T, Yoshinari K, Yamazoe Y, Kamata E, Ono A, Hirose A, Hayashi M.

J Toxicol Sci. 2013;38(2):291-9.


Coordinated roles of pregnane X receptor and constitutive androstane receptor in autoinduction of voriconazole metabolism in mice.

Ohbuchi M, Yoshinari K, Kaneko H, Matsumoto S, Inoue A, Kawamura A, Usui T, Yamazoe Y.

Antimicrob Agents Chemother. 2013 Mar;57(3):1332-8. doi: 10.1128/AAC.01900-12. Epub 2012 Dec 28.


A category approach to predicting the repeated-dose hepatotoxicity of allyl esters.

Yamada T, Tanaka Y, Hasegawa R, Sakuratani Y, Yamada J, Kamata E, Ono A, Hirose A, Yamazoe Y, Mekenyan O, Hayashi M.

Regul Toxicol Pharmacol. 2013 Mar;65(2):189-95. doi: 10.1016/j.yrtph.2012.12.001. Epub 2012 Dec 12.


Inhibition of CYP3A4 by 6',7'-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells.

Araki N, Tsuruoka S, Hasegawa G, Yanagihara H, Omasa T, Enosawa S, Yamazoe Y, Fujimura A.

J Pharm Pharmacol. 2012 Dec;64(12):1715-21. doi: 10.1111/j.2042-7158.2012.01562.x. Epub 2012 Aug 2.


Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling.

Kuribayashi H, Miyata M, Yamakawa H, Yoshinari K, Yamazoe Y.

Eur J Pharmacol. 2012 Dec 15;697(1-3):132-8. doi: 10.1016/j.ejphar.2012.09.048. Epub 2012 Oct 7.


Liver X receptor α bidirectionally transactivates human CYP1A1 and CYP1A2 through two cis-elements common to both genes.

Araki K, Watanabe K, Yamazoe Y, Yoshinari K.

Toxicol Lett. 2012 Nov 23;215(1):16-24. doi: 10.1016/j.toxlet.2012.09.021. Epub 2012 Oct 4.


Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.

Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, Yamashita M, Yanae M, Yamazoe Y, Nishida S.

Leuk Res. 2012 Oct;36(10):1315-22. doi: 10.1016/j.leukres.2012.07.003. Epub 2012 Jul 19.


[A survey of the dosage of zoledronic acid and investigation of the relationship between renal function and adverse events].

Yanae M, Nakao M, Fujiwara K, Kawaguchi A, Tsubaki M, Chiba Y, Morita T, Yamazoe Y, Nishida S.

Gan To Kagaku Ryoho. 2012 Jul;39(7):1093-8. Japanese.


Resistance to acetaminophen-induced hepatotoxicity in glutathione S-transferase Mu 1-null mice.

Arakawa S, Maejima T, Fujimoto K, Yamaguchi T, Yagi M, Sugiura T, Atsumi R, Yamazoe Y.

J Toxicol Sci. 2012;37(3):595-605.


A category approach to predicting the hemolytic effects of ethylene glycol alkyl ethers in repeated-dose toxicity.

Yamada T, Tanaka Y, Zhang H, Hasegawa R, Sakuratani Y, Mekenyan O, Yamazoe Y, Yamada J, Hayashi M.

J Toxicol Sci. 2012;37(3):503-15.


Mechanisms of CYP3A induction by glucocorticoids in human fetal liver cells.

Matsunaga T, Maruyama M, Matsubara T, Nagata K, Yamazoe Y, Ohmori S.

Drug Metab Pharmacokinet. 2012;27(6):653-7. Epub 2012 May 22.


Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19.

Miyata M, Hata T, Yamakawa H, Kagawa T, Yoshinari K, Yamazoe Y.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):41-7. doi: 10.1016/j.jsbmb.2012.04.008. Epub 2012 May 3.


Unimolecular and bimolecular binding system for the prediction of CYP2D6-mediated metabolism.

Sato K, Yamazoe Y.

Drug Metab Dispos. 2012 Mar;40(3):486-96. doi: 10.1124/dmd.111.043125. Epub 2011 Dec 12.


Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice.

Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y.

Biol Pharm Bull. 2011;34(12):1885-9.


Constitutive androstane receptor transactivates the hepatic expression of mouse Dhcr24 and human DHCR24 encoding a cholesterogenic enzyme 24-dehydrocholesterol reductase.

Yoshinari K, Ohno H, Benoki S, Yamazoe Y.

Toxicol Lett. 2012 Jan 25;208(2):185-91. doi: 10.1016/j.toxlet.2011.11.003. Epub 2011 Nov 11.


Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes.

Benoki S, Yoshinari K, Chikada T, Imai J, Yamazoe Y.

Arch Biochem Biophys. 2012 Jan 15;517(2):123-30. doi: 10.1016/ Epub 2011 Nov 10.


Polycyclic aromatic hydrocarbons activate CYP3A4 gene transcription through human pregnane X receptor.

Kumagai T, Suzuki H, Sasaki T, Sakaguchi S, Miyairi S, Yamazoe Y, Nagata K.

Drug Metab Pharmacokinet. 2012;27(2):200-6. Epub 2011 Nov 10.


Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order.

Yamazoe Y, Ito K, Yoshinari K.

Drug Metab Rev. 2011 Nov;43(4):409-39. doi: 10.3109/03602532.2011.624103. Review.


Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma.

Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, Nishida S.

J Exp Clin Cancer Res. 2011 Aug 10;30:74. doi: 10.1186/1756-9966-30-74.


Clioquinol is sulfated by human jejunum cytosol and SULT1A3, a human-specific dopamine sulfotransferase.

Yoshinari K, Sakamoto M, Senggunprai L, Yamazoe Y.

Toxicol Lett. 2011 Oct 10;206(2):229-33. doi: 10.1016/j.toxlet.2011.07.023. Epub 2011 Jul 27.


[Clinical evaluation of calculating carboplatin dosage using Japanese equation for estimating GFR for gynecologic cancer].

Kidera Y, Nakao M, Tsubaki M, Yoshinaga M, Kajitani F, Yanae M, Sakano M, Yamazoe Y, Chiba Y, Moriyama K, Nishida S.

Gan To Kagaku Ryoho. 2011 Jul;38(7):1143-8. Japanese.


Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-κB in HL-60 cells.

Shoji K, Tsubaki M, Yamazoe Y, Satou T, Itoh T, Kidera Y, Tanimori Y, Yanae M, Matsuda H, Taga A, Nakamura H, Nishida S.

Arch Pharm Res. 2011 Mar;34(3):469-75. doi: 10.1007/s12272-011-0316-8. Epub 2011 May 6.


Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.

Hanaoka K, Hosono M, Usami K, Tatsumi Y, Yamazoe Y, Komeya Y, Tsuchiya N, Ishii K, Sumita M.

Nucl Med Commun. 2011 Aug;32(8):678-83. doi: 10.1097/MNM.0b013e328346b32a.


Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions.

Yamaura Y, Yoshinari K, Yamazoe Y.

Drug Metab Pharmacokinet. 2011;26(4):351-63. Epub 2011 Mar 14.


Development of two-dimensional template system for the prediction of CYP2B6-mediated reaction sites.

Koyama N, Yamazoe Y.

Drug Metab Pharmacokinet. 2011;26(4):309-30. Epub 2011 Mar 8.


Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma.

Tsubaki M, Yamazoe Y, Yanae M, Satou T, Itoh T, Kaneko J, Kidera Y, Moriyama K, Nishida S.

Cytokine. 2011 Apr;54(1):100-7. doi: 10.1016/j.cyto.2011.01.005. Epub 2011 Feb 2.


High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.

Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K.

Int J Clin Oncol. 2011 Jun;16(3):244-9. doi: 10.1007/s10147-010-0170-6. Epub 2011 Jan 18.


Supplemental Content

Loading ...
Support Center